Figure 2. The prognostic value of KMT2C mutations in different clinicopathological subgroups. OS: overall survival; PSA: prostate-specific antigen; CAB: combined anti-androgen blockade; ISUP: International Society of Urological Pathology; AR: androgen receptor; DDR: DNA damage response; MAPK: mitogen-activated protein kinase; NED: neuroendocrine differentiation; PI3K: phosphatidylinositol 3-kinase; HR: hazard ratio; CI: confidence interval.